Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00081276 · ClinicalTrials.gov registry record · Phase 2
3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer
A Phase 2 study of Primary Peritoneal Cavity Cancer and Recurrent Ovarian Epithelial Cancer, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT00081276 is a Phase 2 study of Primary Peritoneal Cavity Cancer and Recurrent Ovarian Epithelial Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 48 participants, below the 100-participant average among 15 other Primary Peritoneal Cavity Cancer trials with a reported enrollment target (52% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00081276, a Phase 2 study of Primary Peritoneal Cavity Cancer and Recurrent Ovarian Epithelial Cancer, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
Drugs used in chemotherapy, such as 3-AP and cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. This phase II trial is studying how well giving 3-AP together with cisplatin works in treating patients with recurrent or persistent platinum-resistant ovarian epithelial cancer or primary peritoneal cancer
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- DRUG cisplatin
- DRUG triapine
Study Locations (1)
Pennsylvania
- Gynecologic Oncology Group - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2005-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00081276
The ClinicalTrials.gov registry entry for NCT00081276 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 100-participant average among 15 other Primary Peritoneal Cavity Cancer trials with a reported enrollment target (52% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Primary Peritoneal Cavity Cancer appearing as the primary indexed condition, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00081276 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00081276 about?
NCT00081276 is a clinical study titled "3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer". Drugs used in chemotherapy, such as 3-AP and cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. This phase II trial is studying how well giving 3-AP together with cisplatin works in treating patient...
What is the current status of trial NCT00081276?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2005-07.
What conditions does trial NCT00081276 study?
This clinical trial studies the following conditions: Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer.
What interventions are being tested in trial NCT00081276?
The interventions under investigation include: laboratory biomarker analysis (OTHER), cisplatin (DRUG), triapine (DRUG).
Who is sponsoring clinical trial NCT00081276?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00081276 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Peritoneal Cavity Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer
RECRUITING · Phase 2
-
Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
COMPLETED · Phase 2
-
Irofulven in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cancer
COMPLETED · Phase 2
-
Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer
COMPLETED · Phase 2
-
Temsirolimus in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
COMPLETED · Phase 2
-
Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Metastatic Refractory Ovarian Cancer or Primary Peritoneal Cancer
COMPLETED · Phase 2
Explore more on PlainTrial
Primary Peritoneal Cavity Cancer
All registered trials for this condition
Recurrent Ovarian Epithelial Cancer
All registered trials for this condition
Pennsylvania
All trials with a study site in Pennsylvania
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.